We serve Chemical Name:5-amino-4-bromo-2-methylpyridazin-3-one CAS:65269-63-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:5-amino-4-bromo-2-methylpyridazin-3-one
CAS.NO:65269-63-8
Synonyms:5-amino-4-bromo-2-methyl-2h-pyridazin-3-one
Molecular Formula:C5H6BrN3O
Molecular Weight:204.02500
HS Code:2933990090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:60.91000
Exact Mass:202.96900
LogP:0.70620
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like 5-amino-4-bromo-2-methyl-2h-pyridazin-3-one chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-amino-4-bromo-2-methyl-2h-pyridazin-3-one physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-amino-4-bromo-2-methyl-2h-pyridazin-3-one Use and application,5-amino-4-bromo-2-methyl-2h-pyridazin-3-one technical grade,usp/ep/jp grade.
Related News: Italian medical packaging firm Stevanato Group went public on the Big Board on July 16, raising $672 million and helping push up the fortune of the billionaire Stevanato family behind the company. oxotungsten,tin manufacturers Many specialty and biotech organizations are now relying on external service providers to minimize the costs of manufacturing and in-house development required to develop molecules for new drugs and their subsequent clinical trials, explains Saurabh Gurnurkar, executive director, UQUIFA. iron,oxosilver suppliers François-Henri Boissel, CEO of NOVA, commented: “Grégoire is an industry trail blazer with over two decades of experience in innovation, product strategy and digital entrepreneurship. 8′-oxo-7′,8′-dihydro-6’H-spiro[cyclohexane-1,5′-naphtho[2,3-d][1,3]dioxol]-4-yl acetate vendor & factory Many specialty and biotech organizations are now relying on external service providers to minimize the costs of manufacturing and in-house development required to develop molecules for new drugs and their subsequent clinical trials, explains Saurabh Gurnurkar, executive director, UQUIFA. ,François-Henri Boissel, CEO of NOVA, commented: “Grégoire is an industry trail blazer with over two decades of experience in innovation, product strategy and digital entrepreneurship.
